Artificial Intelligence-assisted Glaucoma Screening (AIAGS)
Overview
This study will develop an artificial intelligence (AI) program for the screening of glaucoma.
Full Title of Study: “The Development of Artificial Intelligence-assisted Glaucoma Screening Program”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: October 1, 2020
Detailed Description
We have realized that the glaucomatous optic neuropathy is irreversible. But if early detection and early intervention can be performed to control the development of the disease, it can greatly reduce the blindness rate of glaucoma, improve the life quality and physiological and mental health of patients, and alleviate the social burden. Therefore, screening and early diagnosis of glaucoma is the focus of glaucoma prevention. China has a population of 1.3 billion, which greatly increase the difficulty of disease screening. In recent years, the intersection of artificial intelligence (AI) technology and modern medicine has made efficient and rapid disease screening possible.
Interventions
- Diagnostic Test: Fundus Image
- Fundus image of optic nerve
Arms, Groups and Cohorts
- Fundus Image
- Glaucomatous and Non-glaucomatous fundus images that have been taken from the last 5 years in Shanghai General hospital.
Clinical Trial Outcome Measures
Primary Measures
- The specificity of the algorithm for diagnosing glaucoma
- Time Frame: from January 2020 to March 2021
- The specificity of the algorithm for diagnosing glaucoma will be calculated …
- The sensitivity of the algorithm for diagnosing glaucoma
- Time Frame: from January 2020 to March 2021
- The sensitivity of the algorithm for diagnosing glaucoma will be calculated .
Participating in This Clinical Trial
Inclusion Criteria
- able to complete fundus images Exclusion Criteria:
- unable to complete fundus images
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Provider of Information About this Clinical Study
- Principal Investigator: Haiyan Wang, Attending of Ophthalmology, M.D. Ph.D. – Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Overall Official(s)
- Haiyan Wang, Ph.D., Principal Investigator, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Overall Contact(s)
- Haiyan Wang, Ph.D., +86 15000096256, catherinecnc81@126.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.